S6.14.2 – Goals of the Stephen A. Harrison Patient Advocacy Fellowship Program
In this conversation, the organizers of the Stephen A. Harrison Patient Advocacy Fellowship Program discuss their goals for the program.
October 9, 2025
In this conversation, the organizers of the Stephen A. Harrison Patient Advocacy Fellowship Program discuss their goals for the program.
In this conversation, we learn about how the Stephen A. Harrison Patient Advocacy Fellowship Program started and meet the program organizers and five of the initial Fellows.
Louise Campbell and Roger Green interview Wayne Eskridge and Elena Samsonova of the Fatty Liver Foundation and five of the first class of Harrison fellows about the new Dr. Stephen A. Harrison Patient Advocacy Fellowship program.
In this conversation from April, Naim Alkhouri joins Roger Green to reminisce about his long relationship with Stephen Harrison and announce his (then) new role as Chief Academic Officer at Summit Clinical Research.
Dr. Kristina Curtis joins Jörn Schattenberg, Louise Campbell and Roger Green to wrap up the Steatotic Think-Thank on SLD, Mike Betel shares lessons from his 30-day Glucose Challenge, and Naim Alkhouri remembers Stephen Harrison while sharing his vision for the future of clinical trials and medical education.
Hepatologist and Hepatology Key Opinion Leader Sven Francque joins Jörn Schattenberg, Louise Campbell and Roger Green to discuss other agents in development with unique modes of action and the ways that metabolic vs. pleiotropic effects will drive future drug choices.
Global Liver Institute President and CEO Larry Holden joins Roger Green to discuss policy changes in Washington, some potential effects for the liver community, and ways to preserve what is possible.
On the first anniversary of Stephen Harrison’s passing, we take an episode to remember our co-founder and colleague, Stephen Harrison, his contributions to MASH and how his legacy moves forward.
The opening portion of SurfingMASH’s April roundtable on drug development looks at developments in the FGF-21 mode of action and, more generally, treatment of patients with cirrhosis, with tremendous enthusiasm.
This week’s expert, hepatologist and Key Opinion Leader Mazen Noureddin, discusses exciting advances in MASH and cirrhosis drug development for multiple modes of action.